European Archives - Page 503 of 1369 - European Medical Journal

Interview: Michael Camilleri

One of the wonderful opportunities I’ve had over the years is to interact and go across specialties, divisions, or departments. Here at Mayo Clinic, there’s a wonderful legacy of cross-disciplinary research…

ESHRE 2024 Interview: Karen Sermon

I went to medical school in Brussels, but I knew very early on that I didn’t want to practice, I wanted to go into research. So, I looked…

Spotlight: July 2024

Catch up on the top pharma news stories of July in EMJ GOLD’s monthly round-up, including insights on pharma’s use of social media.

Long-Term Lung Damage Persists in COVID-19 Survivors

A recent study shows many COVID-19 survivors have lasting lung issues and reduced pulmonary function three years post-hospitalization, highlighting the need for ongoing care.

Donor Background Affects Stem Cell Transplant Success

Did you know that the socioeconomic background of a donor may affect the success of hematopoietic stem cell transplantation?

Multidisciplinary Approach Mitigates Refracture Risk for Adults with Hip Fracture

Refracture risk in adult patients who sustain a hip fracture can be mitigated through a new multidisciplinary approach, including fall prevention and anti-osteoporosis medication use.

Pregnancy Hope after Stem Cell Transplant

A new study from University Hospital Carl Gustav Carus, Dresden, Germany, has shed light on the viability of pregnancy following hematopoietic stem cell transplantation.

Safely Tapering Glucocorticoids in Patients with Systemic Lupus Erythematosus

New study shows that gradual tapering of glucocorticoid steroids in mSACQ state SLE patients can be done without increasing flare risk.

Eli Lilly’s weight loss drug shows promise in heart failure

The weight loss drug reduces the risk of hospitalisation, death and more for adults with obesity and a common form of heart failure.

Improved Precision in Thyroid Cancer Detection

Researchers conducted a prospective diagnostic study to explore whether differences in patients’ RAS variants reflected variance in the status of their tumours.